TITLE

Bill seeks to bring FDA's blurry lines into focus

AUTHOR(S)
Wechsler, Jill
PUB. DATE
December 1997
SOURCE
Managed Healthcare;Dec97, Vol. 7 Issue 12, p22
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the legislation that clarifies the United States Food and Drug Administration regulations. Allowing of pharmaceutical companies to disseminate competent healthcare economic information to sophisticated purchasers; Allowing of drugmakers to distribute peer-reviewed journal articles describing unapproved product uses; Production of limited quantities of medications for individualized patient therapy.
ACCESSION #
14092

 

Related Articles

  • Ban the Bromate.  // Nutrition Action Health Letter;Oct99, Vol. 26 Issue 8, p2 

    Focuses on the efforts of the United States Food and Drug Administration to ban bromate in baked goods. Adverse effects of potassium bromate; Brands that still use potassium bromate.

  • New molecular entities.  // Formulary;Sep97, Vol. 32 Issue 9, p881 

    Presents several drugs approved by the US Food and Drug Administration. Sodium capsules for the management of pain; Tablets for the treatment of advanced breast cancer; Dopamine agonist for the treatment of Parkinson's disease.

  • FDA issues reprint guidelines.  // Dermatology Times;Jan1996, Vol. 17 Issue 1, p68 

    Reports that the Food and Drug Administration will be issuing guidelines, permitting distribution of journal reprints studies, that support an approved indication, but make reference to unapproved uses. What companies will be allowed to distribute; Guidelines concerning IND submission.

  • FDA Safety Page. Holquist, Carol // Patient Care;1/15/2002, Vol. 36 Issue 1, p54 

    Focuses on the drug name review process created by the U.S. Food and Drug Administration in January 2002. Handwriting and verbal analyses; Computer assisted analysis; Evaluation of risks.

  • Consumer groups blast FDA reform legislation.  // Health Facilities Management;Sep97, Vol. 10 Issue 9, p10 

    Focuses on the legislation aimed at reforming the US Food and Drug Administration, led by retired Senator Howard Metzenbaum. Bill that was approved by the Senate Labor and Human Resources Committee; One of the provisions that is troubling Metzenbaum.

  • Close call. Conlan, Michael F. // Drug Topics;12/8/97, Vol. 141 Issue 23, p101 

    Looks at United States Food and Drug Administration (FDA), reform on the protection legislation for pharmacies, with reference to House and Senate conferees. Limits of the FDA authority; Importance of federal law; Information FDA reform package.

  • More changes & challenges at FDA. Wechsler, Jill // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p24 

    Reports on changes, challenges and issues arising from efforts to implement policies required by the enacted US Food and Drug Administration Modernization Act. Improvement in quality and processing of drug marketing applications; Increase of new-drug and product applications; Comments on the...

  • How to comment on proposals and submit petitions. Henkel, John // FDA Consumer;Apr96, Vol. 30 Issue 3, p6 

    Part I. Provides tips on how to comment on proposals and submit petitions to the Food and Drug Administration (FDA). FDA's announcement of new regulations or revisions in the `Federal Register' journal; Requirements for petitions to be submitted to the agency; Public meetings and hearings. ...

  • FDA Bans Colloidal Silver Products, Cites Lack of Data.  // FDA Consumer;Nov/Dec99, Vol. 33 Issue 6, p5 

    Reports on the ruling finalized by the United States Food and Drug Administration on drug products containing colloidal siver or silver salts. Effect of the products on some people's skin; Why the colloidal silver products are misbranded; Final rule on any colloidal silver product intended to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics